Skip to content
Search
Home
About Us
About APLAR
APLAR Milestones
President Message
Committees
APLAR Directors
Executive Committee
Other Committees
Membership
Member National Organizations
Constitution
Membership Application
Membership Update
Academy
APLAR Academy
Governance
Membership
Short Course
Upcoming Course
Past Course
Academy Webinar
Upcoming Webinar
Past Webinar
Grand Round
Upcoming Grand Round
Past Grand Round
Discussion Forum
Grand Round Blackboard
ASPIRE Grant
About APLAR ASPIRE
ASPIRE Core Training Modules
ASPIRE Implementation Toolkit
About SIG
AYR
ABOUT AYR
AYR Board
Committee
AYR Membership
AYR Webinar
Upcoming Webinar
Past Webinar
AYR Blackboard
Discussion Forum
Collaboration
APLAR ESOR
ESOR Application
Post Event Submission
Online Submission
EULAR School of Rheumatology
Exchange Programme
Exchange Programe Application
Online Submission
EULAR Exchange Program
APLAR MNO Patronage
Patronage Application
Online Submission
EULAR Collaborations
Center Of Excellence
APLAR CoEs
New Application
Renew CoE Application
Online Submission
Grants and Awards
Grant
COPCORD Grant
Congress Travel Grant
Research Grant
Fellowship Grant
Award
Master Award
Events
Congress
Upcoming Congress
Past Congress
Events
Upcoming Events
Past Events
Gallery
Publications
Published Journal
SIG Publication
COVID – 19 Publication
IJRD
Voice Of APLAR
Patient Education
APLAR Grand Round Blackboard 2023
Step
1
of
2
50%
Question 1
Which of the following statements are true?
Question 1
A. Generalized morphea may cause sclerodactyly.
B. Skin biopsy findings can differentiate between morphea and systemic sclerosis.
C. Arthralgia is the most common extracutaneous manifestation of morphea.
D. There is an infiltration of predominantly macrophages and plasma cells in the skin lesions due to morphea.
E. Anti-topoisomerase II alpha antibody is much more commonly found in patients with morphea than in patients with other autoimmune diseases.
Your Answer is Incorrect
Answer with Detailed explanation
A. False
Morphea is differentiated from systemic sclerosis by the absence of sclerodactyly, Raynaud’s phenomenon and nailfold capillary changes.
B. False
Morphea and systemic sclerosis share similar histopathologic features.
C. True
D. False
A perivascular infiltrate of predominantly lymphocytes with admixed rare plasma cells and eosinophils is seen in the reticular dermis in the early stage of morphea and systemic sclerosis.
E. True
Anti-topoisomerase II alpha is found in 76% of all patients with morphea and 85% of patients with generalised morphea. On the other hand, it is encountered in only 14% of patients with systemic sclerosis and 8% of patients with SLE.
Your Answer is Correct
Answer with Detailed explanation
A. False
Morphea is differentiated from systemic sclerosis by the absence of sclerodactyly, Raynaud’s phenomenon and nailfold capillary changes.
B. False
Morphea and systemic sclerosis share similar histopathologic features.
C. True
D. False
A perivascular infiltrate of predominantly lymphocytes with admixed rare plasma cells and eosinophils is seen in the reticular dermis in the early stage of morphea and systemic sclerosis.
E. True
Anti-topoisomerase II alpha is found in 76% of all patients with morphea and 85% of patients with generalised morphea. On the other hand, it is encountered in only 14% of patients with systemic sclerosis and 8% of patients with SLE.
Question 2
Which one of the following is the first-line pharmacological agent to treat morphea?
Question 2
A. Hydroxychloroquine
B. Methotrexate
C. Azathioprine
D. Mycophenolate mofetil
E. Cyclosporine
Your Answer is Incorrect
Answer with Detailed explanation
B. Methotrexate
Methotrexate is the current first-line treatment for subtypes of morphea with severe skin affection or musculoskeletal involvement.
Reference
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011 Feb 1;64(2):217-28.
Knoblet R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology. 2017 Sep;31(9):1401-24.
By Dr A T M Tanveer Hasan, Associate Professor of Rheumatology, Enam Medical College & Hospital, Savar, Dhaka, Bangladesh
Your Answer is Correct
Answer with Detailed explanation
B. Methotrexate
Methotrexate is the current first-line treatment for subtypes of morphea with severe skin affection or musculoskeletal involvement.
Reference
Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. Journal of the American Academy of Dermatology. 2011 Feb 1;64(2):217-28.
Knoblet R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology. 2017 Sep;31(9):1401-24.
By Dr A T M Tanveer Hasan, Associate Professor of Rheumatology, Enam Medical College & Hospital, Savar, Dhaka, Bangladesh
If you can’t view the question please click
here
.
Past APLAR Grand Round Blackboard
1st APLAR Grand Round 2022 Blackboard
2nd APLAR Grand Round 2022 Blackboard
3rd APLAR Grand Round 2022 Blackboard
4th APLAR Grand Round 2022 Blackboard
5th APLAR Grand Round 2022 Blackboard